ILLUMINA NASDAQ: ILMN
Background of Illumina
- Illumina Inc an American company that develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
- Illumina Inc provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets.
- Illumina Inc customers include genomic research centres, pharmaceutical companies, academic institutions, clinical research organisations, and biotechnology companies.
- Illumina Inc’s headquarters are in San Diego, California.
- By 2014 Illumina Inc’s technology had allegedly reduced the cost of sequencing a human genome to US$1,000, down from $1 million in 2007.
- Today, Illumina Inc oversees a high-value product portfolio which technologies are used by academic, government, pharmaceutical, biotechnology, and other leading institutions worldwide.
- Illumina Inc has a rich history that dates back 1998 when David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee founded it.
- In 1999, Illumina Inc acquired Spyder Instruments for their technology of high-throughput synthesis.
- Illumina Inc started to offer single nucleotide polymorphism (SNP) genotyping services in 2001 and launched its first system in 2002, using GoldenGate Genotyping technology.
- Illumina Inc currently offers microarray-based products and services for an expanding range of genetic analysis sequencing, including SNP genotyping, gene expression, and protein analysis.
- In June 2009, Illumina Inc announced the launch of their own Personal Full Genome Sequencing Service.
- Until 2010, Illumina Inc only sold instruments “for research use only” but in early 2010, the company obtained FDA approval for its BeadXpress system to be used in clinical tests and they could open their own CLIA lab and begin offering clinical genetic testing itself.
- Illumina Inc acquired Epicentre Biotechnologies in Madison, Wisconsin, in 2011.
- In 2014, Illumina Inc announced a multimillion-dollar product, HiSeq X Ten, that it forecast would provide large-scale whole-genome sequencing for $1,000/genome. Illumina already held 70% of the market for genome-sequencing machines.
- In late 2015, Illumina Inc spun off the company GRAIL, focused on blood testing for cancer tumours in the bloodstream.
- In 2017 Illumina Inc received funding from Bill Gates and Jeff Bezos investing $100 million in series A funding, and with Illumina maintaining a 20% holding share in Grail.
- [Illumina Inc worked with a blood test trial with over 120 000 women during scheduled mammogram visits in the states of Minnesota and Wisconsin, as well as a partnership with the Mayo Clinic.
- Today, Illumina Inc is truly one of the most valuable healthcare companies in the world with a market capitalization of US$ 70.6 billion recorded in July 2025.
- In 2025 the total staff compliment for Illumina Inc was more than 7 800.
- Illumina Inc’s executive leadership team consists of: John Wendell Thompson – Independent Chairman of the Board; Francis A. deSouza – President, Chief Executive Officer, Director; Sam A. Samad – Chief Financial Officer; Robert Ragusa – Chief Operations Officer; and Aimee L. Hoyt – Chief People Officer.
Illumina Shares Growth Driver
- As such, the company’s innovative and competitive portfolio has allowed it to defy the market trends surrounding the coronavirus pandemic, with performance and shares still attractive after a tumultuous
- Illumina Inc customers include genomic research centres, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
- Thanks to a massive base of more than 17,000 analysis machines in operation globally, a majority of Illumina Inc’s revenue is highly recurring.
- When customers use the hardware, they also need to use the compatible sequencing kits or genotyping arrays each time and as a result, sales of these consumables made up 71% of the company’s total revenue in 2025.
- This proportion is slowly increasing over time relative to instrument sales and service contracts and it also means that every instrument sale implies a significant amount of additional revenue over time.
- Once customers are comfortable to operate within the Illumina Inc product ecosystem, they will hardly defect to a lower-cost competitor.
- Illumina Inc management expects revenue to grow by as much as 20% in 2025, probably be driven by new sequencing hardware sales, which could rise by as much as 33% year over year.
- If that happens, investors can look forward to even more revenue growth over the next few years as customers burn through consumables for their newly acquired machines.
- In the meantime, Illumina Inc’s quarterly earnings may bounce back to its pre-pandemic norm.
Illumina Investor Tip
- Illumina Inc trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol ILMN. Illumina Inc forms part of both the NASDAQ-100 and S&P 500 Components.
- An analysis on Illumina Inc’s market performance and income statement indicates Revenue (ttm) of 3.47 billion, Revenue Per Share (ttm) 23.67, Quarterly Revenue Growth (yoy) 27.20%, Gross Profit (ttm) 2.23 billion, EBITDA 748 million, Net Income Avi to Common (ttm) 630 million and Diluted EPS (ttm) 4.28.
- Illumina Inc is a provider of sequencing- and array-based solutions for genetic analysis and operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc.
- Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of much valued genomic solutions.
- Illumina Inc’s portfolio of integrated systems, consumables and analysis tools addresses the full range of genomic complexity, price points, and throughput, enabling customers to choose the best solution for their research.
- Illumina Inc has been gaining from consecutive segmental growth and increased demand for its products.
- Illumina Inc’s focus on partnerships and worldwide expansion to drive growth are expected to contribute further although stiff competition and a tough funding environment remain concerns.
- Illumina Inc projects 7% growth over the next five years and expects to maintain segmental performance.
- Illumina Inc delivered a stable performance despite the economic impact which resulted from the global coronavirus pandemic. This stable performance can be largely owed to the company’s diverse portfolio, as well as its strong medical supplies sector which witnessed growing demand as hospitals geared up to combat the virus.
- With sound financials and significant, consistent, and continuous growth forecasted for the remainder of 2025, shareholders who buy or sell shares can expect lucrative dividends and returns.
- Overall, the company’s a stable performance has resulted in healthy dividends and a good share price for investors who choose to purchase shares today, securing a decent buy-in in 2025 and in the future.
- For more information regarding the company’s forecast, the buy or sell of shares and the live price chart, visit the company’s online Investor Relations page.
- Data from this analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.
Sector
Healthcare
Industry
Diagnostics & Research
Sub industry
Biotech
Latest News
Illumina: How to buy Illumina Shares Online
Here are the steps you need to follow to buy Illumina Inc shares with utmost confidence:
- Navigate to the AvATrade website and select ‘Register’.
- Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
- As soon as your account application has been reviewed and approved, you can select your trading platform from AvATrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
- Once you have downloaded the trading platform of your choice, you can use your AvATrade live account details to log into your AvATrade account on the trading platform.
- From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘Illumina Inc’ or ‘ILMN’ to buy/purchase shares.
- Alternatively, you can make use of AvATrade’s online Web Trader or the AvATradeGo mobile application.
Trading CFDs and Stocks with AvATrade provides traders with the following benefits:
- Leverage of up to 1:20.
- Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
- Indices, stocks, and commodities can all be traded form a single screen.
- Client support is presented live in a multitude of languages.
- Traders have exclusive access to a variety of educational tools.
- Trades can be executed across multiple platforms.
More shares that can be purchased through AvATrade, can be viewed here.
FAQ
Can I buy Illumina Inc shares in South Africa?
Yes, you can.
How to buy Illumina Inc shares?
By simply opening a free account with SA Shares, or by clicking the “Buy this Share” button to get started.
What is the current share price?
By clicking on the link provided above, you can view the real-time Illumina Inc share price on the platform.
Is Illumina Inc a good share to buy?
Yes, it is. Despite the growing concerns surrounding Covid-19, Illumina Inc is continuing manufacturing, sales and delivery of its products and it is forecasted to be one of the very few automotive companies to make a significant rebound post-Covid-19.
Can I buy Illumina Inc CFD through SA Shares?
Yes, you can.
Top 4 Brokers
